Shares of Tempus AI (TEM), a leader in leveraging artificial intelligence (AI) for precision medicine, surged 7.05% in pre-market trading on Thursday. The rally came amidst growing expectations that the availability of cost-efficient AI models from emerging players like DeepSeek could drive wider adoption of AI-powered healthcare solutions.
DeepSeek, a Chinese AI company, has recently gained attention for its large language models (LLMs) that are significantly cheaper to train and deploy compared to expensive U.S. models like OpenAI's GPT-4. By optimizing model architectures and training processes, DeepSeek claims to achieve similar performance at a fraction of the cost, potentially disrupting industries reliant on AI-driven automation, including healthcare.
For companies like Tempus AI, the availability of affordable AI models could be a game-changer. Tempus AI's AI-enabled platform, Tempus Next, identifies care gaps and provides clinicians with actionable insights, supporting access to guideline-directed treatments. By integrating cost-effective AI models like DeepSeek's, Tempus AI could enhance its platform's capabilities while reducing development and deployment costs, fostering broader adoption of AI-driven precision medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.